WEDNESDAY, Aug. 6, 2014 (HealthDay News) -- Taking aspirin every day appears to reduce the odds of developing and dying from colon, stomach or esophageal cancer, a new study suggests.
Based on a review of available studies, researchers determined that the benefits of aspirin therapy for preventing cancer outweigh the risks. Millions of people already take this inexpensive drug to prevent or treat heart disease.
"We came to the conclusion that most people between the ages of 50 and 65 would benefit from a daily aspirin," said lead researcher Jack Cuzick, head of the Center for Cancer Prevention at Queen Mary, University of London.
"It looks like if everyone took a daily aspirin, there would be less cancer, and that would far outweigh any side effects," added Cuzick.
Gastrointestinal bleeding is the most serious side effect associated with aspirin.
Taking aspirin for 10 years could cut colon cancer risk by around 35 percent and deaths from colon cancer by 40 percent, the researchers reported Aug. 6 in the Annals of Oncology.
Daily aspirin also can reduce the risk of esophageal and stomach cancers by 30 percent and deaths from these cancers by 35 to 50 percent, the investigators reported.
Dr. Leonard Lichtenfeld, deputy chief medical officer at the American Cancer Society, said this study falls short of a recommendation that everyone take aspirin to prevent cancer. "But it rises to the level that people should have a discussion with their doctor," he said.
However, Lichtenfeld pointed out that the evidence for aspirin's benefits is circumstantial. "These are not randomized trials, which provide us with the best quality evidence to answer the question. You don't have a study that compares aspirin with no aspirin," he said.
Although the studies reviewed for this report don't prove aspirin prevents cancer, they offer strong evidence that it might, Lichtenfeld said.
Still, taking aspirin has risks. "Some people will be at risk of stomach bleeding, but very few," Cuzick said.
People 60 years old who take daily aspirin for 10 years have an increased risk of stomach bleeding of about 3.6 percent. Bleeding could be life-threatening in less than 5 percent of people who develop bleeding, the researchers noted.
The risk of serious bleeding, however, increases dramatically after age 70. Cuzick recommends that people 70 and older not start taking aspirin to prevent cancer because of this increased risk.
Peptic ulcers are another side effect of aspirin. The studies the authors reviewed cited an increased risk of 30 to 60 percent for these stomach lesions.
In terms of benefits, it's still unknown what dose of aspirin provides the maximum protection, Cuzick said.
"The evidence suggests that low-dose aspirin (75 milligrams) is as effective as the standard dose of 300 milligrams, but there has been no direct comparison," he said. "So people should take the low dose, but research should be done to see if the standard dose is even more effective."
Cuzick said aspirin's protective effect doesn't appear to kick in until it's taken for at least five years, and probably 10 years, between the ages of 50 and 65. No benefit was seen in the first three years, and it's not clear if taking aspirin for more than a decade will reap greater benefits, he said.
Taking an aspirin daily should not be seen as a reason not to be screened for cancer, Lichtenfeld cautioned. "Screening has an important impact on reducing colon cancer," he said.
As to why aspirin is protective, Cuzick can only speculate. It's known that aspirin interferes with blood-clotting by reducing platelets in the blood. Platelets are thought to help cancer cells travel throughout the body, so limiting them might make it harder for cancer cells to spread.
Another theory is that aspirin, an anti-inflammatory agent, might stop cells from dividing. This lowers the odds that a cell will mutate when it divides, Cuzick explained. "You are less likely to have a mutation that will cause cancer," Cuzick said.
For more about aspirin and cancer, visit the American Cancer Society.
SOURCES: Jack Cuzick, Ph.D., head, Center for Cancer Prevention, Queen Mary, University of London, England; Leonard Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society; Aug. 6, 2014, Annals of Oncology
All rights reserved